Valeria Fantin, Sanofi global head of oncology research

Sanofi turns to a Jen­nifer Doud­na gene edit­ing up­start for next-gen NK cell al­liance

Big Phar­mas — as well as more than a few biotechs — are on the hunt for the best, cut­ting-edge gene edit­ing tech avail­able, and to­day we can tell you about Sanofi’s choice.

The Paris-based gi­ant’s head of on­col­o­gy re­search and its chief of ge­nom­ic med­i­cine have set­tled on Scribe Ther­a­peu­tics’ CasX edit­ing tech for their work on NK cells. And the deal with the Jen­nifer Doud­na spin­out comes with a $25 mil­lion get-to-know-you up­front and a cool $1 bil­lion in biobuck mile­stones, pro­vid­ed they can neat­ly knock down all the pins in the deal.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.